50200dkk
-1,6 %
Date:2025-03-20Time:17:20:00Latest report:Q4-2024List:Mid CapTicker:GUBRA
Market Cap:8 208 mdkkEnterprise Value:8 170 mdkkNet Sales:265,7 mdkkEarnings:-36,5 mdkkEmployees:0ISIN:DK0062266474

Ratios

10-year key figure history for Gubra turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Gubra with index and moving average MA50 and MA200.

Stockprice:502,00
MA50:609,68
MA200:565,51
Price/MA200:-11,2 %
RSI (14):40,3
Price/MA50:-17,7 %

Description

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business.

Pharmaceuticals